UK company record
Quell Therapeutics
Cell therapy (engineered T-regulatory cells)
CandidateCore UK
Snapshot
- UK location
- London · London
- Sector
- Biotech & techbio
- Latest recorded round
- Series B
- Latest recorded amount
- $156M
- Date
- 2021-11-01
Legal-identity layer
Candidate identity.
- Selected legal name
- QUELL THERAPEUTICS LIMITED
- Company number
- 11890040
- Companies House status
- active
- Incorporated
- 2019-03-19
Investors
- Fidelity Management & Research CompanyLead
- Jeito CapitalLead
- Ridgeback Capital InvestmentsLead
- SV Health InvestorsLead
- SynconaParticipant
- AlbionVCParticipant
Current directors and active controllers
- BESHAR, Luke MatthewCurrent director
- BINGHAM, Catherine Elizabeth, DameCurrent director
- CLANCY, AnnetteCurrent director
- LECHLER, Robert Ian, SirCurrent director
- LONG-MCGIE, Jeffrey StephenCurrent director
- MCGILL, Iain RobertCurrent director
- PATEL, Dhavalkumar D, DrCurrent director
- PETRIS, Elisa Michela, DrCurrent director
- RIVERS, Tyrell JermaineCurrent director
- Syncona LimitedActive controller
- ASHRAFIAN, Houman, Professordirector
- FUEYO, Alberto Sanchez, Professordirector
- MEARS, Rachel Brookedirector
- MITRE SECRETARIES LIMITEDcorporate-secretary
- MURPHY, Martin Patrick, Drdirector
- RHIND, Stephen Keithdirector
- Syncona Portfolio LimitedFormer controller
Funding rows
- Series B$156M · 2021-11-01
Sources
- https://www.prnewswire.com/news-releases/quell-therapeutics-raises-156-million-in-oversubscribed-series-b-financing-to-advance-its-pioneering-multi-modular-engineered-t-regulatory-treg-cell-therapy-pipeline-and-platform-301432188.html
- https://www.insideprecisionmedicine.com/news-and-features/quell-therapeutics-well-placed-to-advance-treg-cell-therapy-platform-with-156m-series-b/
- https://www.insideprecisionmedicine.com/news-and-features/quell-therapeutics-well-placed-to-advance-treg-cell-therapy-platform-with-156m-series-b/